Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (731-740 of 869) with videos related to

Pageof 87
Sort By:
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
The Lancet. Haematology|September 16, 2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a studyKevin R Kelly, Sikander Ailawadhi, David S Siegel, et al.
Blood|March 13, 2008
Targeting NF-kappaB in Waldenstrom macroglobulinemiaXavier Leleu, Jérôme Eeckhoute, Xiaoying Jia, et al.
Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 29, 2010
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumorsMichel de Weers, Yu-Tzu Tai, Michael S van der Veer, et al.
Blood|August 5, 2004
Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell functionAbie Craiu, Yoriko Saito, Ana Limon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
Blood Advances|July 18, 2022
Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myelomaElizabeth K O'Donnell, Yael N Shapiro, Andrew J Yee, et al.
British Journal of Haematology|May 29, 2010
Monoclonal gammopathy of undetermined significance: a consensus statementJames R Berenson, Kenneth C Anderson, Robert A Audell, et al.
Blood Advances|October 15, 2021
Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISHYuting Yan, Xiaoqi Qin, Jiahui Liu, et al.
Pageof 87

Showing results (731-740 of 869) with videos related to

Sort By:
Pageof 87
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
The Lancet. Haematology|September 16, 2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a studyKevin R Kelly, Sikander Ailawadhi, David S Siegel, et al.
Blood|March 13, 2008
Targeting NF-kappaB in Waldenstrom macroglobulinemiaXavier Leleu, Jérôme Eeckhoute, Xiaoying Jia, et al.
Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 29, 2010
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumorsMichel de Weers, Yu-Tzu Tai, Michael S van der Veer, et al.
Blood|August 5, 2004
Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell functionAbie Craiu, Yoriko Saito, Ana Limon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
Blood Advances|July 18, 2022
Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myelomaElizabeth K O'Donnell, Yael N Shapiro, Andrew J Yee, et al.
British Journal of Haematology|May 29, 2010
Monoclonal gammopathy of undetermined significance: a consensus statementJames R Berenson, Kenneth C Anderson, Robert A Audell, et al.
Blood Advances|October 15, 2021
Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISHYuting Yan, Xiaoqi Qin, Jiahui Liu, et al.
Pageof 87